Blinatumomab (Blincyto®) (paediatric ALL)


Assessment Status Rapid Review complete
Drug Blinatumomab
Brand Blincyto®
Indication Treatment of paediatric patients aged 1 year and older with Philadelphia chromosome negative B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation
Assessment Process
Rapid review commissioned 15/01/2019
Rapid review completed 30/01/2019
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of blinatumomab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations; May 2019